Phase 3 Trial of Ecopipam for Tourette Syndrome: Safety and Efficacy Evaluation

This Phase 3 randomized clinical trial evaluates the safety and maintenance of effect of ecopipam, a selective dopamine D1 receptor antagonist, for up to 24 weeks in children, adolescents, and adults with Tourette syndrome. The study includes 216 participants in the open-label pe